Effectiveness of mRNA COVID-19 Vaccines and Hybrid Immunity in Preventing SARS-CoV-2 Infection and Symptomatic COVID-19 Among Adults in the United States

被引：0

作者：

Feldstein, Leora R. ^{[1
]}

Ruffin, Jasmine ^{[1
]}

Wiegand, Ryan E. ^{[1
]}

Borkowf, Craig B. ^{[1
]}

James-Gist, Jade ^{[1
]}

Babu, Tara M. ^{[2
]}

Briggs-Hagen, Melissa ^{[1
]}

Chappell, James ^{[3
]}

Chu, Helen Y. ^{[2
]}

Englund, Janet A. ^{[4
]}

Kuntz, Jennifer L. ^{[5
]}

Lauring, Adam S. ^{[6
]}

Lo, Natalie ^{[2
]}

Carone, Marco ^{[2
]}

Lockwood, Christina ^{[2
]}

Martin, Emily T. ^{[7
]}

Midgley, Claire M. ^{[1
]}

Monto, Arnold S. ^{[7
]}

Naleway, Allison L. ^{[5
]}

Ogilvie, Tara ^{[2
]}

Saydah, Sharon ^{[1
]}

Schmidt, Mark A. ^{[5
]}

Schmitz, Jonathan E. ^{[3
]}

Smith, Ning ^{[5
]}

Sohn, Ine ^{[3
]}

Starita, Lea ^{[2
]}

Talbot, H. Keipp ^{[3
]}

Weil, Ana A. ^{[2
]}

Grijalva, Carlos G. ^{[3
]}

机构：

[1] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Coronavirus & Other Resp Viruses Div, Atlanta, GA 30329 USA

[2] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA USA

[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[4] Univ Washington, Seattle Childrens Res Inst, Dept Pediat, Seattle, WA USA

[5] Kaiser Permanente Ctr Hlth Res, Portland, OR USA

[6] Univ Michigan, Dept Internal Med, Div Infect Dis, Ann Arbor, MI USA

[7] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2025年

关键词：

COVID-19; vaccine effectiveness; hybrid immunity; cohort study; prior infection;

D O I：

10.1093/infdis/jiaf007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background Understanding protection against SARS-CoV-2 infection by vaccine and hybrid immunity is important for informing public health strategies as new variants emerge.Methods We analyzed data from 3 cohort studies spanning 1 September 2022 to 31 July 2023 to estimate COVID-19 vaccine effectiveness (VE) against SARS-CoV-2 infection and symptomatic COVID-19 among adults with and without prior infection in the United States. Participants collected weekly nasal swabs irrespective of symptoms, participated in annual blood draws, and completed periodic surveys, which included vaccination status and infection history. Swabs were tested molecularly for SARS-CoV-2. VE was estimated by Cox proportional hazards models for the hazard ratios of infections, adjusting for covariates. VE was calculated considering prior infection and recency of vaccination.Results Among 3344 adults, the adjusted VE of a bivalent vaccine against infection was 37.2% (95% CI, 12.3%-55.7%) within 7 to 59 days of vaccination and 21.1% (95% CI, -0.5% to 37.1%) within 60 to 179 days of vaccination when compared with participants who were unvaccinated or had received an original monovalent vaccine dose >= 180 days prior. Overall, the adjusted VE of a bivalent vaccine against infection, in conjunction with prior infection, was 62.2% (95% CI, 46.0%-74.5%) within 7 to 179 days of vaccination and 39.4% (95% CI, 12.5%-61.6%) at >= 180 days when compared with naive participants who were unvaccinated or had received a monovalent vaccine dose >= 180 days prior.Conclusions Adults with prior infection and recent vaccination had high protection against infection and symptomatic illness. Recent vaccination alone provided moderate protection. According to data from 3 prospective cohort studies where participants collected weekly nasal swabs, protection from COVID-19 vaccination against SARS-CoV-2 infection and symptomatic illness was highest among adults with prior infection and recent vaccination. Recent vaccination alone provided moderate protection.

引用

页数：11